



## 저작자표시-비영리-동일조건변경허락 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.
- 이차적 저작물을 작성할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



동일조건변경허락. 귀하가 이 저작물을 개작, 변형 또는 가공했을 경우에는, 이 저작물과 동일한 이용허락조건하에서만 배포할 수 있습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

# Highly expressed Reptin administers aggressive features in ovarian cancer

BO WOOK KIM)

Department of Medicine

The Graduate School, Yonsei University



# Highly expressed Reptin administers aggressive features in ovarian cancer

Directed by Professor JAE-HOON KIM

The Doctoral Dissertation  
submitted to the Department of Medicine,  
the Graduate School of Yonsei University  
in partial fulfillment of the requirements for the degree  
of Doctor of Philosophy

BO WOOK KIM

December 2020

This certifies that Doctoral Dissertation  
of BO WOOK KIM is approved.

-----  
Thesis Supervisor: JAE-HOON KIM

-----  
Thesis Committee Member#1: YONGIL KWON

-----  
Thesis Committee Member#2: SUNGHOON KIM

-----  
Thesis Committee Member#3: YONG-MAN KIM

-----  
Thesis Committee Member#4: JAE YONG CHO

The Graduate School  
Yonsei University

December 2020

## ACKNOWLEDGEMENTS

As I conclude my thesis, I would like to express my sincere gratitude to the many people who have helped me successfully complete my PhD program over the past 10 years. First of all, I would like to thank Professor Jae-Hoon Kim for his generous encouragement and guidance so that he could devote himself to research during his doctoral program. In addition, I would like to thank Professors Yongil Kwon, Sunghoon Kim, Yong-Man Kim, and Jae Yong Cho, who were in charge of reviewing thesis and spared no valuable advice. I am also grateful to Joon Yong Jung PhD for guiding me and giving me a lot of inspiration at NIH. In addition, I would like to thank Eun-Ju Lee for helping me with the experiment and giving me a lot of advice when I face difficulties.

I would like to thank my parents and sister for their unconditioned love and support. Also, I would like to express my gratitude to my eternal companion and my beloved wife, Mi Kyoung Kim, who has given me so much inspiration. No amount of success in my life would be possible if not for them.

## <TABLE OF CONTENTS>

|  |    |
|--|----|
| ABSTRACT .....   | 1  |
| I. INTRODUCTION .....  | 3  |
| II. MATERIALS AND METHODS .....  | 5  |
| 1. Patients and tumor specimens .....  | 5  |
| 2. Immunohistochemistry (IHC) and scoring .....  | 5  |
| 3. SYBR green real-time PCR .....  | 6  |
| 4. Western Blotting .....  | 7  |
| 5. Gene Expression Omnibus (GEO) dataset analysis .....  | 7  |
| 6. Cell culture and transfection of siRNAs .....   | 7  |
| 7. Cell proliferation assay .....  | 8  |
| 8. Cell cycle .....  | 8  |
| 9. Cell invasion and migration assay .....   | 8  |
| 10. In vivo xenograft tumor model .....  | 9  |
| 11. Statistics .....   | 9  |
| III. RESULTS .....   | 11 |
| 1. Reptin expression in ovarian cancer tissue and cell lines .....   | 11 |
| 2. Down-regulation of Reptin decreases cell proliferation, invasion<br>and migration in ovarian cancer cells ..... | 16 |
| 3. Down-regulation of Reptin reduces tumor growth in nude mice<br>xenograft .....                                  | 20 |
| IV. DISCUSSION .....   | 22 |
| V. CONCLUSION .....  | 24 |
| REFERENCES .....   | 25 |
| ABSTRACT(IN KOREAN) .....  | 28 |
| PUBLICATION LIST .....   | 30 |

## LIST OF FIGURES

|  |    |
|--|----|
| Figure 1. Reptin protein expression with IHC staining and analysis of clinical significance in ovarian cancer .....            | 14 |
| Figure 2. Reptin showing high expression in human ovarian cancer cells .....   | 15 |
| Figure 3. Effects of Reptin on proliferation and cell cycle of Reptin-knockdown ovarian cancer cells .....                     | 17 |
| Figure 4. Invasion, migration assays of TOV112D, OVCA429 was determined by Matrigel assay 48 hr after siRNA transfection ..... | 19 |
| Figure 5 Down-regulation of Reptin reduces tumor growth in nude mice xenograft.....  | 21 |

## LIST OF TABLES

|  |    |
|--|----|
| Table 1. Patients' clinicopathologic characteristics in IHC samples.....   | 11 |
| Table 2. Association of Reptin protein expression with clinicopathological characteristics in ovarian cancer ..... | 13 |



## ABSTRACT

### **Highly expressed Reptin administers aggressive features in ovarian cancer**

Bo Wook Kim

*Department of Medicine  
The Graduate School, Yonsei University*

(Directed by Professor Jae-Hoon Kim)

**Objective:** Reptin is one of the ATPases of the AAA+ (ATPases Associated with various cellular Activities) superfamily and has been reported to have a multifunctional role in carcinogenesis. However, its biologic and prognostic significance in ovarian cancer has not yet been investigated. In this study, we evaluated the clinical significance and functional role of Reptin in ovarian cancer.

**Methods:** The study included benign ovarian tumor tissues (n=175), borderline cancer (n=55) and ovarian cancer tissues (n=271). In order to identify Reptin expression, immunohistochemistry (IHC) was performed, and then the association of Reptin with various prognostic factors was investigated. Reptin's functional roles in cell proliferation and the cell cycle were determined by invasion and migration assays and an in vivo study after its knockdown with shRNA in ovarian cancer cell lines.

**Results:** Reptin was over-expressed in ovarian cancer compared with normal, benign, and borderline tumors in IHC tissue samples ( $p < 0.001$ ). High expression of Reptin relative to low expression was correlated with

poor progression-free survival ( $p = 0.014$ ) but showed tendency of decreased overall survival ( $p = 0.071$ ). Down-regulation of Reptin decreased cell proliferation in OVCA429 with siRNA and in TOV112D with siRNA ( $p < 0.001$ ). Down-regulation of Reptin with siRNA significantly decreased migration and invasion of OVCA429 and TOV112D ovarian cancer cells ( $p < 0.001$ , respectively). According to the results of the in vivo study, tumor growth decreased in down-regulated Reptin tumors with shRNA 1 and 2 compared to control group ( $p$  value  $< 0.05$ , respectively) while tumor incidence rate diminished in Reptin stably expressed tumor.

Conclusion: Our data showed that Reptin is highly expressed in ovarian cancer and is associated with poor progression-free survival outcome. Inhibition of Reptin decreased malignant properties. Overall, our results suggest that Reptin may be an effective target in treatment of ovarian cancer.

---

Key words: Reptin, ovarian cancer, survival outcome, tumor cell viability

## **Highly expressed Reptin administers aggressive features in ovarian cancer**

Bo Wook Kim

*Department of Medicine  
The Graduate School, Yonsei University*

(Directed by Professor Jae-Hoon Kim)

### **I. INTRODUCTION**

Ovarian cancer is the second most common cause of gynecologic cancers following the uterine corpus<sup>1</sup>. Ovarian cancer incidence in Korea has been increasing steadily; now, it is the third most common gynecologic cancer but the leading cause of cancer death<sup>2</sup>. Unfortunately, most ovarian cancers are diagnosed in the advanced stage, due to the lack of both specific symptoms in the early stage and a cost-effective screening test; and late-diagnosed ovarian cancer, is of high lethality. In advanced ovarian cancer cases, the standard treatment includes cytoreductive surgery and chemotherapy. Additionally, molecular-biologic advances entailing the introduction of target therapies such as bevacizumab to ovarian cancer have demonstrated modest survival gains<sup>3</sup>. Recently, PARP inhibitors improved survival in women with ovarian cancer of Homologous recombination deficiency (HRD) or BRCA mutation<sup>4</sup>. However, ovarian cancer mortality remains high owing to frequent disease recurrence and chemo-resistance. Ovarian cancer still shows a veiled tumorigenesis mechanism, and ovarian tumor heterogeneity disrupts ovarian cancer conquest<sup>5</sup>. Given its veiled mechanism and high lethality, treatment of ovarian cancer is a both a challenging and an urgent issue requiring further biologic investigation.

Previously, we identified Reptin in a study involving immunoprecipitation of tumor-associated antigen (TAA) and autoantibody in ovarian cancer. We hypothesized that autoantibodies corresponding to TAA were elevated in pre-relative to post-treatment serum because surgical removal and adjuvant chemotherapy reduce the tumor volume and, in turn, decreases serum levels of TAA and autoantibodies. Pre- and post-treatment autoantibodies in patients with ovarian cancer were obtained and, in recognized 36 proteins after immunoprecipitation, Reptin, a molecular weight of 48.5kDa, was identified<sup>6</sup>.

Reptin is one of the ATPases of the AAA+ (ATPases Associated with various cellular Activities) superfamily, and has been reported to have a multifunctional role in carcinogenesis<sup>7</sup>. Reptin is involved in ATP hydrolysis by hexamerization with pontin and induces structural modification of nucleosome and, eventually, regulation of transcription<sup>8</sup>. Its roles in cancer include or are related to transcriptional regulation, DNA damage repair, the cell cycle, and cell proliferation<sup>9-11</sup>. Overexpression of Reptin has been identified in various cancers including kidney, liver and gastric cancer<sup>12-14</sup>. Overexpression of Reptin also is associated with poor prognosis in renal cell carcinoma<sup>13</sup>.

In light of such accumulating evidence, it is expected that Reptin plays a key role in tumorigenesis and cancer prognosis. However, its biologic and prognostic significance has yet to be elucidated for ovarian cancer, though decreased survival outcomes have been reported for liver, colorectal, and breast cancer patients showing high Reptin expression. Therefore, in this study, we investigated functional role and clinical significance of Reptin in ovarian cancer.

## II. MATERIALS AND METHODS

### 1. Patients and tumor specimens

The study enrolled 501 patients who had been diagnosed with benign ovarian tumor (n=175), Borderline ovarian cancer (n=55) and ovarian cancer (n=271) between 1996 and 2011 at Gangnam Severance Hospital, Yonsei University College of Medicine (Seoul, Korea) along with 90 matched non-adjacent normal ovarian epithelium cases. Some of the paraffin blocks were provided by the Korea Gynecologic Cancer Bank through the Bio & Medical Technology Development Program of the Ministry of Education, Science and Technology, Korea (NRF-2017M3A9B8069610). The patients' data including age, cancer stage, tumor differentiation, cell type, lymph node (LN) metastasis, chemosensitivity and clinical outcomes were collected. The tumor stage was determined based on the International Federation of Gynecology and Obstetrics (FIGO) scale and was histologically classified according to the World Health Organization (WHO) grades. Patients with operability indications underwent hysterectomy with pelvic and para-aortic LN dissection. Chemotherapy resistance was designated as "recurrence" within 6th months after chemotherapy, while chemotherapy sensitivity was designated as "no recurrence" within 6th months after chemotherapy. This study was approved by the Institutional Review Board of Gangnam Severance Hospital (IRB #3-2010-0030).

### 2. Immunohistochemistry (IHC) and scoring

For IHC staining, all of the paraffin sections were cut to 5 mm thickness, deparaffinized through xylene and dehydrated with graded ethanols. Endogenous peroxidase activity was blocked by 3% H<sub>2</sub>O<sub>2</sub> in methanol, and primary incubations were performed using anti-Reptin antibody (rabbit monoclonal, abcam) at a dilution of 1:300 for 1 hr 30min at room temperature followed by detection using Dako LSAB+ (Dako, Glostrup, Denmark). The reaction product was developed with DAB (3,3'-diaminobenzidine) chromogen

solution (Dako). The tissue sections were lightly counterstained with hematoxylin. Representative photomicrographs were recorded using a digital camera (Nikon, Tokyo, Japan). Staining was scored as positive when tumor or epithelial cells showed cytoplasmic immunoreactivity. The IHC staining results were scored based on staining intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong) and the percentage of positive cells (1 = 0 – 25%, 2 = 26 – 50%, 3 = 51 – 75%, 4 = 76 – 100% positive cells). For the immunostaining score, the intensity of staining was categorized as 0 (no staining), 1+ (weak), 2+ (moderate) and 3+ (strong); the percentage of staining was categorized as 1+ (0 - 25%), 2+ (26 - 50%), 3+ (51 - 75%) and 4+ ( $\geq$  75%). The final IHC score was calculated based on the combined intensity and percentage scores (range: 0–12).

### 3. SYBR green real-time PCR

Total RNA was extracted by the Trizol method. cDNA synthesis was performed with the SuperScript™ III First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA). SYBR green real-time polymerase chain reaction (PCR) was performed using primer sets specific for Reptin (forward primer: 5'-AAG ACA CGA AGC AGA TCC T-3'; reverse primer: 5'- TGT CAT CCA CCT GCA CTT C-3') and the housekeeping gene  $\alpha$ -actin (forward primer: 5'- ATT AAG GAG AAG CTG TGC TAC GTC-3'; reverse primer: 5'- ATG ATG GAG TTG AAG GTA GTT TCG-3'), MMP1 (forward primer: 5'- AGC CAT CAC TTA CCT TGC ACT-3'; reverse primer: 5'- TTC TAG AGT CGC TGG GAA GC-3'), MMP2 (forward primer: 5'- GAT ACC CCT TTG ACG GTA AGG A-3'; reverse primer: 5'- CCT TCT CCC AAG GTC CAT AGC-3'), MMP9 (forward primer: 5'- AGA CGG GTA TCC CTT CGA CG-3'; reverse primer: 5'- AAA CCG AGT TGG AAC CAC GAC-3').  $\alpha$ -actin was used for quantitative normalization of the cDNA used for PCR. The relative gene expression level was determined by  $2^{-\Delta\Delta C_t}$  analysis.

#### 4. Western Blotting

Whole-cell extraction was conducted using PRO-PRE Protein Extraction Solution (Intron Biotechnology, Seongnam, Korea). Equal amounts (20  $\mu$ g) of each sample were separated on 8-15% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked with 5% non-fat dry milk in TBST (50 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.5) for 1 hr at room temperature, washed with TBST, and subsequently incubated with primary antibodies: anti-Reptin (abcam), anti- $\alpha$ -actinin (H-2) (Santa Cruz Biotechnology, Dallas, TX, USA). Primary antibodies against each protein were detected by secondary antibodies conjugated with horseradish peroxidase (GE Healthcare, Munich, Germany). Specific bands for each protein were detected on AGFA X-ray film (Agfa Health Care, Mortsel, Belgium) using the SuperSignal Chemiluminescence kit (Thermo Scientific, Rockford, IL, USA).

#### 5. Gene Expression Omnibus (GEO) dataset analysis

Gene expression profiling data was obtained from the published microarray data of the GSE27651, GSE26712, GSE18520 and GSE14407 datasets from GEO. Identification of differentially-expressed Reptin was conducted with a sorting tool based on Microsoft Excel software (Probe number: 202264\_s\_at on affymatrix human U133A platform; gene accession number: NM\_006144.). Box plots were drawn and statistical analyses were performed using Graphpad Prism 6 software.

#### 6. Cell culture and transfection of siRNAs

All of the experiments were performed with two human ovarian cancer cell lines, TOV112D and OVCA429. Cells were maintained in DMEM (GIBCO, CA, USA). Media were supplemented with 10% fetal bovine serum (GIBCO) as well as antibiotics solutions (GIBCO) at 37°C in an incubator under a 5%-CO<sub>2</sub>, 95%-humidified atmosphere. Suppression of Reptin expression was performed

using specific siRNA targeted for Reptin (1: GCUCCACGCAGAC AUGAAGGAGUA and 2: GAUCCGGGAAGGGAAGAUU, Invitrogen) or control siRNA (Stealth RNAi™ siRNA Negative Control Med GC, Invitrogen) using RNAiMAX (Invitrogen) as a transfection reagent according to the manufacturer's instructions. The cells were harvested 48 hr after transfection, and reduction of protein levels was confirmed by Western blotting.

#### 7. Cell proliferation assay

Cell proliferation was assessed using the high-sensitivity WST-1 assay (DaeilLab, Seoul, Korea). Control or Reptin-siRNA-transfected cells were seeded at  $1 \times 10^4$  cells/well onto 96-well microtiter plates in a final volume of 100  $\mu$ L/well. The cells were incubated with WST-1 at 37°C for 1 hr, and the optical density (OD) values at 450 nm were recorded at days 0, 1, and 2 using a 96-well microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

#### 8. Cell cycle

TOV112D and OVCA429 were harvested 48 hr after siRNA transfection in a 6 cm dish. Cells were fixed with 70% ethanol and washed with washing buffer (0.01% Triton X-100 in PBS). Cells were suspended in 200  $\mu$ L of a RNase A (100  $\mu$ g/ml), PI (50  $\mu$ g/ml) in the washing buffer and then subjected to 1 hr incubation after adding 800  $\mu$ L. Cells were washed with washing buffer and then suspended in washing buffer (200  $\mu$ L). After transfer to a FACS tube, 800  $\mu$ L of washing buffer was added to each tube, and analyzed by FACS Canto II flow cytometry (BD Biosciences, San Jose, CA, USA).

#### 9. Cell invasion and migration assay

Cell invasion and migration were performed using a boyden chamber (Neuro Probe 48-Well Micro Chemotaxis Chamber, Neuro Probe, Inc., Gaithersburg, MD, USA) according to the manufacturer's instructions. The invasion and



migration assays were performed using membranes coated with Matrigel (BD Transduction Lab, San Jose, CA, USA) and collagen, respectively. Preparatorily, the cells were treated with either control or Reptin siRNA for 48 hr. Cells ( $1 \times 10^5$ ) suspended in 0.1% FBS medium (56  $\mu$ L) were added to the upper chamber. The lower chamber was filled with medium containing 1% FBS (27  $\mu$ L). After 24 hours of incubation, the membrane was stained with the Differential Quick Stain Kit (Triangle Biomedical Sciences, Inc., Durham, NC, USA). Invading cells in six randomly selected fields were counted using Microscope Axio Imager.M2 (magnification x200; Carl Zeiss, Thornwood, NY, USA). Each experiment was repeated three times.

#### 10. In vivo xenograft tumor model

All animal procedures were performed under a protocol approved by the Institutional Animal Care and Use Committee of Gangnam Severance Hospital. A mouse xenograft model was used with nude female BALB/C mice aged 4-5 weeks (OrientBio Inc., Sungnam, Gyunggi, Korea). TOV112D cells ( $1.5 \times 10^6$  cells/inoculation) were incubated in 100  $\mu$ L of Matrigel (BD Biosciences, San Jose, CA, USA) and PBS mixture (1:1) and injected subcutaneously in both flanks of each mouse. Five weeks after inoculation, tumor volumes were measured using the following formula: tumor volume ( $\text{mm}^3$ ) =  $(L \times W^2)/2$ , where L is the length and W is the width. The data were recorded as means  $\pm$  standard errors.

#### 11. Statistics

A non-parametric Mann-Whitney U test was used to assess the statistical significance of the Reptin mRNA expression difference between HOSE cells and ovarian cancer cell lines and tissues. IHC scores were compared using a one-way ANOVA test and independent t-test. The IHC cut-off for high expression of tumor markers was determined by receiver operating

characteristic (ROC) curve analysis. The sensitivity and specificity for dead/alive discrimination were plotted for each IHC score, thus generating an ROC curve. The cut-off value was established to be the point on the ROC curve where the sum of sensitivity and specificity was maximized. Kaplan-Meier survival analysis was performed to determine the association of Reptin expression with disease-free and overall survival, and the survival curves were compared among the groups using log-rank tests. All of the analyses were performed using Statistical Package for Social Science for Windows, version 22.0 (SPSS Inc., Chicago, IL, USA).

### III. RESULTS

#### 1. Reptin expression in ovarian cancer tissue and cell lines

Table 1 summarizes the patients' clinicopathological characteristics in their IHC samples. Included are 501 patients with ovarian tumor, 175 patients with benign tumor, 55 patients with borderline cancer, 246 patients with epithelial ovarian cancer, and 25 patients with non-epithelial ovarian cancer.

Table 1. Patients' clinicopathologic characteristics in IHC samples

|                               | N   | %    |
|-------------------------------|-----|------|
| Diagnostic Category           |     |      |
| Normal ovarian epithelium     | 90  | 15.2 |
| Benign                        | 175 | 29.6 |
| Borderline cancer             | 55  | 9.3  |
| Epithelial ovarian cancer     | 246 | 41.6 |
| Non-epithelial ovarian cancer | 25  | 4.2  |
| FIGO stage                    |     |      |
| I                             | 43  | 16.7 |
| II                            | 17  | 6.6  |
| III                           | 145 | 56.2 |
| IV                            | 28  | 10.9 |
| Recurrent                     | 25  | 9.7  |
| Cell type                     |     |      |
| Serous adenocarcinoma         | 174 | 67.4 |
| Mucinous adenocarcinoma       | 27  | 10.5 |
| Endometrioid adenocarcinoma   | 27  | 10.5 |
| Clear cell carcinoma          | 13  | 5    |
| Others                        | 17  | 6.6  |
| Tumor differentiation         |     |      |
| Well                          | 15  | 8.8  |
| Moderate                      | 71  | 41.5 |
| Poor                          | 85  | 49.7 |
| Chemotherapy resistance       |     |      |
| Sensitive                     | 171 | 72.2 |
| Resistant                     | 66  | 27.8 |

FIGO, International Federation of Gynecology and Obstetrics

According to the FIGO scale, 43 patients were stage I, 17 stage II, 145 stage III, and 28 stage IV. The most common cell type was serous adenocarcinoma (174 patients), and the most common tumor differentiation was “poor” grade (85 patients). Among 237 patients receiving chemotherapy, 171 (72.2%) showed sensitivity.

We examined the association of Reptin expression with the clinicopathological characteristics in ovarian cancer, as shown in Table 2. High expression of Reptin was observed in ovarian cancer relative to normal, benign and borderline ovarian tumor ( $P < 0.001$ , respectively). However, there was no statistically significant difference in Reptin expression with regard to FIGO stage, cell type, tumor differentiation or chemoresistance. Figure 1 plots the Reptin IHC expression in ovarian cancer and provides an analysis of its clinical significance. The representative Reptin IHC expressions are shown in Figure 1 A, B, C, D, E, F, G, H. Reptin expression was clearly observed in the cytoplasm. As indicated in Fig. 1I, Reptin expression was significantly higher in ovarian cancer than in normal epithelium, benign or borderline tumor ( $p < 0.001$ ). High expression of Reptin was correlated with poor progression-free survival ( $p = 0.014$ ) in Fig. 1J but showed a trend of decreasing OS (G) ( $p = 0.071$ ) relative to those with low Reptin expression in Fig. 1K.

Figure 2A shows the Reptin mRNA levels measured by real-time PCR in human ovarian surface epithelial (HOSE) cells and ovarian cancer cell lines. A total of 15 cancer cell lines were significantly expressed over 5 HOSE cells in terms of the Reptin mRNA level ( $p < 0.001$ ). Figure 2B shows Reptin protein levels by Western blotting, 17 ovarian cancer cell lines showing higher expression than 5 HOSE cells with statistical significance ( $p < 0.05$ ). Figure 2C shows mRNA expression levels of Reptin as analyzed for ovarian cancer patients in the Gene Expression Omnibus (GEO) database; Reptin over-expression was confirmed in ovarian cancer with statistical significance.

Table 2. Association of Reptin protein expression with clinicopathological characteristics in ovarian cancer

|                         | N   | Mean IHC score<br>(95% CI) | <i>p value</i>   |
|-------------------------|-----|----------------------------|------------------|
| Diagnostic Category     |     |                            | <i>&lt;0.001</i> |
| Normal                  | 90  | 3.4 (2.9-3.9)              |                  |
| Benign                  | 163 | 2.3 (1.9-2.7)              |                  |
| Borderline cancer       | 55  | 3.2 (2.4-4.0)              |                  |
| Cancer                  | 236 | 6.3 (5.8-6.8)              |                  |
| Recurrent               | 22  | 5.5 (3.9-7.2)              |                  |
| FIGO stage              |     |                            | <i>0.114</i>     |
| I                       | 43  | 6.2 (5.1-7.3)              |                  |
| II                      | 17  | 4.0 (2.5-5.4)              |                  |
| III                     | 145 | 6.6 (6.1-7.2)              |                  |
| IV                      | 28  | 6.2 (4.6-7.9)              |                  |
| Recurrent               | 25  | 6.0 (4.4-7.6)              |                  |
| Cell type               |     |                            | <i>0.202</i>     |
| Serous adenocarcinoma   | 174 | 6.5 (5.9-7.1)              |                  |
| Mucinous adenocarcinoma | 27  | 5.2 (3.8-6.7)              |                  |
| Others                  | 57  | 5.9 (5.0-6.8)              |                  |
| Tumor differentiation   |     |                            | <i>0.384</i>     |
| Well + moderate         | 86  | 6.2 (5.5-7.0)              |                  |
| Poor                    | 85  | 6.7 (5.9-7.6)              |                  |
| Chemotherapy resistance |     |                            | <i>0.287</i>     |
| Sensitive               | 171 | 6.2 (5.6-6.7)              |                  |
| Resistant               | 66  | 6.8 (5.8-7.8)              |                  |

FIGO, International Federation of Gynecology and Obstetrics




Figure 1. Reptin protein expression with IHC staining and analysis of clinical significance in ovarian cancer. Representative IHC staining for cytoplasmic

Reptin in ovarian tissues: (A) no staining in normal ovarian epithelium, (B) weak staining intensity in papillary serous adenocarcinoma, (C) moderate staining intensity in papillary serous adenocarcinoma, (D) strong intensity in papillary serous adenocarcinoma. Scale bar: 200 $\mu$ m. The percentage of staining: (E) 0 ~ 25%, (F) 26 ~ 50%, (G) 51 ~ 75%, (H) 76 ~ 100% positive cells. Reptin expression was higher in ovarian cancer than normal epithelium, benign, and borderline tumor tissues (I). Poor 5-year progression-free survival (J) ( $p = 0.014$ ) and trend of decreasing OS (K) ( $p = 0.071$ ) in high Reptin expression.




Figure 2. Reptin showing high expression in human ovarian cancer cells. A.


Reptin mRNA levels were measured by real-time PCR in human ovarian surface epithelial (HOSE) cells and ovarian cancer cell lines. The box plots represent the expression levels of Reptin compared between HOSE and ovarian cancer cells. B. Reptin protein levels by Western blot. The intensities of the bands were measured, and the values corrected by  $\alpha$ -actinin were represented in box plots. C. mRNA expression levels of Reptin were analyzed for ovarian cancer patients in Gene Expression Omnibus (GEO) database (GEO accession numbers: GSE27651, GSE26712, GSE18520 and GSE14407). Normal, Human ovarian surface epithelial (HOSE) tissue or cell. An asterisk (\*) indicates a P value  $<0.05$ , a double asterisk (\*\*) indicates a p value  $<0.01$ , a triple asterisk (\*\*\*) indicates a p-value  $<0.001$

## 2. Down-regulation of Reptin decreases cell proliferation, invasion and migration in ovarian cancer cells


To evaluate the function of Reptin in ovarian cancer cells, down-regulation of Reptin with siRNA was performed. We selected TOV112D and OVCA429, which presented high and moderate expression of Reptin mRNA and protein, respectively. Suppression of Reptin was performed using two specific siRNA targeted for Reptin. After transfection of siRNA into OVCA 429 and TOV112D, whole-cell lysates were collected, and down-regulation of Reptin with siRNA was confirmed (Figure 3A1). Cell proliferation of TOV112D and OVCA429 was measured by WST-1 assay at 0, 1, and 2 days, showing that cell proliferation was significantly reduced with siRNA of si-Reptin #1 and #2 at 2 days (Figure 3B). The cell cycle after knockdown of Reptin was evaluated in Figure 3C, confirming cell arrest in the G1 phase in TOV112D and OVCA429 after down-regulation of Reptin.



### A. Down-regulation of Reptin by siRNA in ovarian carcinoma cells



### B. Cell proliferation after down-regulation of Reptin



### C. Cell cycle after down-regulation of Reptin





Figure 3. Effects of Reptin on proliferation and cell cycle of Reptin-knockdown ovarian cancer cells. A. Whole-cell lysates were collected from TOV112D,


OVCA429 cells following Reptin knockdown by si-RNA#1(s1) and #2(s2). Expression of Reptin protein was analyzed by immunoblot.  $\alpha$ -actinin was included as an internal loading control. B. Cell proliferation of TOV112D, OVCA429 was measured by WST-1 assay at 0, 1, and 2 days after siRNA transfection. Error bars represent the SD of triplicate experiments. C. Knockdown of Reptin in TOV112D and OVCA429 cells resulted in cell arrest in G1 phase of cell cycle. An asterisk (\*) indicates a P value  $<0.05$ , a double asterisk (\*\*) indicates a p value  $<0.01$ , a triple asterisk (\*\*\*) indicates a p-value  $<0.001$

Figure 4 shows a cell migration and invasion assay of down-regulated Reptin in ovarian cancer cells. Down-regulation of Reptin with siRNA significantly decreased migration and invasion of OVACA429 and TOV112D in ovarian cancer cells, as indicated in Fig. 4 A and B ( $p<0.001$ , all assay). The cell migration assay of OVCA429 and TOV112D presented decreased cell migration in si-Reptin #1 and #2 treated ovarian cancer cells relative to the negative control. Cell invasion in siRNA #1- and #2-treated OVCA429 and TOV112D decreased according to a Boyden chamber assay. In Figure 4C, matrix metalloproteinase (MMP) was investigated to evaluate migration and invasion activity after siRNA transfection in OVCA429 and TOV112D. The levels of MMP 1 and 2 in siRNA-treated TOV112D and OVCA429 were significantly decreased compared with the control group. The knock-down of Reptin expression by si-Reptin significantly decreased MMP expression in TOV 112D but not in OVCA429 ( $p<0.05$  and  $p=0.156$ , respectively).

### A. Migration assay



### B. Invasion assay



### C. MMP




Figure 4. Invasion, migration assays of TOV112D, OVCA429 was determined by Boyden chamber assay 48 hr after siRNA transfection. A, B. Down-regulation of Reptin with siRNA significantly decreased migration and invasion

of OVCA429 and TOV112D of ovarian cancer cells in Figure 4 A and B ( $p < 0.001$ , all assay). C. Level of MMP 1 and 2 in siRNA-treated TOV112D and OVCA429 was significantly decreased compared with control group. The siRNA-treated TOV112D showed significantly decreased MMP9, whereas the siRNA-treated OVCA429 did not show any MMP9 ( $p < 0.05$  and  $p = 0.156$ , respectively). An asterisk (\*) indicates a P value  $< 0.05$ , a double asterisk (\*\*) indicates a p value  $< 0.01$ , a triple asterisk (\*\*\*) indicates a p-value  $< 0.001$

### 3. Down-regulation of Reptin reduces tumor growth in nude mice xenograft

To investigate the role of Reptin in tumor growth, an in vivo study with TOV112D entailing xenografts into nude mice was performed (Figure 5 A and B). At 5 weeks post-inoculation, tumor growth decreased with shRNA 1 and 2 volume in down-regulated Reptin tumor (Figure 5A). The mean tumor volume was measured to  $4417.6 \pm 1209.1 \text{ mm}^3$  in pLKO.1 control,  $2081.7 \pm 1151.9 \text{ mm}^3$  in siRNA 1 and  $360.6 \pm 253.8 \text{ mm}^3$  in siRNA 2, showing statistical significance (Figure 5B) (p value  $< 0.05$ ).




Figure 5. Down-regulation of Reptin reduces tumor growth in nude mice xenograft. Tumor growth decreased with shRNA 1 and 2 volume in down-regulated Reptin tumor at 5 weeks post-inoculation. asterisk (\*) indicates a P value <0.05,

#### IV. DISCUSSION

We previously identified Reptin overexpression in ovarian cancer by using immunoprecipitation of autoantibody and TAA. In the current study, we then further validated our findings, determining that Reptin was highly expressed in ovarian cancer and that its downregulation inhibited tumor cell proliferation, invasion, migration and growth in ovarian cancer.

Indeed, by IHC, Reptin protein was found to be highly expressed in ovarian cancer relative to normal ovaries and benign cysts. Reptin, as an ATP-dependent chromatin remodeling complex, has been known to function and exist in the nucleus as well. However, in the current study, Reptin was localized in the cytoplasm in addition to the nucleus as shown in Figure 1. This finding of cytoplasmic expression has also been detected in liver cancer<sup>14</sup>. Although Reptin has functions as a transcriptional factor in the nucleus, its existence in the cytoplasm has been determined to depend on the cancer type. Cytoplasmic redistribution of Reptin has been suggested to have a role in mitosis, having shown tubulin assembly/stabilization and remodeling of mitotic complex in hepatocellular carcinoma cells<sup>15</sup>.

Reptin mRNA levels were significantly elevated in ovarian cancer cell lines and tissues relative to HOSE cells. The IHC results of this study indicated high expression of Reptin protein in ovarian cancer compared with normal, benign and borderline tumors of the ovary. In addition, high expression of Reptin protein showed decreased progression-free survival, even though only borderline significance of overall survival was observed on Kaplan-Meier plots. The survival significance of Reptin is rarely reported. Ren et al. reported that cytoplasmic expression of Reptin was correlated with poor overall survival in renal cell carcinoma<sup>13</sup>. Cytoplasmic expression of Reptin has been correlated with poor histologic grade in renal cell carcinoma. Our present results are the first reported on the prognostic significance of Reptin in ovarian cancer showing its cytoplasmic expression. The functional role of Reptin in the cytoplasm has not

been revealed clearly, though cytoplasmic expression of Reptin has been suggested to be related to PIKK-mediated signaling in nonsense-mediated mRNA decay<sup>16</sup>. In addition, relocalization of Reptin is associated with a mitotic apparatus showing possible involvement in mitosis exit<sup>15</sup>. Reptin's functional role in the cytoplasm might be implicated in carcinogenesis; further investigation and determination, for example, of survival significance are required before any firm conclusions can be drawn in this regard.

After down-regulation of Reptin, ovarian cancer cells clearly showed decreased (inhibited) proliferation and arrested cell cycle in Figure3. This finding is concomitant with previous reports. Reptin is suggested to have an important role as a transcriptional oncogenic regulator through interaction with other transcriptional factors related to tumorigenesis<sup>8,17,18</sup>. Reptin-binding TIP60 complex as been reported to have histone acetyltransferase activity and to regulate chromatin remodeling, which is essential for DNA transcription<sup>19</sup>. Reptin was suggested to be an essential activator of MYC oncogenic protein, which acts as a transcriptional regulator and is involved in cell proliferation, the cell cycle, and anti-apoptosis<sup>20,21</sup>. The Reptin-binding MYC domain is essential for oncogenic transcription of cell proliferation and the cell cycle. A missense-mutant Reptin induced apoptosis and inhibited cell growth even though MYC was overexpressed. This finding indicates that Reptin is an essential activator of MYC oncogenic activation<sup>21</sup>. Similarly, Reptin has been reported to be a co-activator of transcriptional factor E2F1, which is a key regulator of the cell cycle<sup>22</sup>. Reptin was recruited by transcriptional factor E2F1, and Reptin/E2F1 complex regulated the promoter region of E2f target genes, eventually activating the cell cycle and tumor cell progression in hepatocellular carcinoma<sup>22</sup>. Similarly, cell-cycle arrest was confirmed by showing G1 phase arrest after down-regulation of Reptin in our results. Cell-cycle regulation of Reptin has been reported to be involved in telomerase activity and hTERT regulation<sup>23</sup>. Telomerase, comprising telomerase reverse transcriptase (TERT), the telomerase RNA component (TERC) and the

TERC-binding protein dyskerin, protects telomere from DNA damage during the cell cycle. Reptin and Pontin complex are involved in facilitation of telomerase assembly by accumulation of TERT and TERC. Reptin-binding TERT has been shown to be higher in the S phase than in G2 and M phases, and Reptin depletion is known to decrease telomerase accumulation, thereby demonstrating its important role in telomerase assembly<sup>23</sup>.

Our results showed that down-regulation of Reptin inhibited cell invasion, migration and metastasis. This finding is consistent with a previous study on renal cell carcinoma cell lines<sup>13</sup>. Reptin down-regulation induced vimentin depletion, which is a key marker of epithelial-mesenchymal transition (EMT) for cancer invasion, migration, and metastasis. Reptin was reported to decrease KAI1, one of the tumor suppressor genes, and antagonistic regulation of beta-catenin-Reptin and the Tip60 coactivator complexes against KAI1 gene increased tumor cell invasion in prostate cancer<sup>10</sup>. Unfortunately, our results did not indicate any association between Reptin expression and lymph node metastasis or tumor stage. Heterogenicity of ovarian cancer produces complex variables, and will require more investigation before any data relevant to clinical application is available.

## V. CONCLUSION

Our data indicated that Reptin is highly expressed in ovarian cancer and is associated with poor progression-free survival outcome. Inhibition of Reptin decreased tumor cell growth and viability. Overall, our results suggest that Reptin may be an effective target in treatment of ovarian cancer.



## REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA: a cancer journal for clinicians*. 2019;69(1):7-34.
2. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017. *Cancer research and treatment : official journal of Korean Cancer Association*. 2020;52(2):335-350.
3. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. *The Lancet Oncology*. 2017;18(6):779-791.
4. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *The New England journal of medicine*. 2018;379(26):2495-2505.
5. Wentzensen N, Poole EM, Trabert B, et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2016;34(24):2888-2898.
6. Kim S, Cho H, Nam EJ, et al. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer. *Genes, chromosomes & cancer*. 2010;49(7):585-595.
7. Torreira E, Jha S, López-Blanco JR, et al. Architecture of the pontin/reptin complex, essential in the assembly of several macromolecular complexes. *Structure (London, England : 1993)*. 2008;16(10):1511-1520.
8. Rosenbaum J, Baek SH, Dutta A, et al. The emergence of the conserved AAA+ ATPases Pontin and Reptin on the signaling landscape. *Science signaling*. 2013;6(266):mr1.
9. Ikura T, Ogryzko VV, Grigoriev M, et al. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. *Cell*. 2000;102(4):463-473.

10. Kim JH, Kim B, Cai L, et al. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. *Nature*. 2005;434(7035):921-926.
11. Matias PM, Baek SH, Bandejas TM, et al. The AAA+ proteins Pontin and Reptin enter adult age: from understanding their basic biology to the identification of selective inhibitors. *Frontiers in molecular biosciences*. 2015;2:17.
12. Li W, Zeng J, Li Q, et al. Reptin is required for the transcription of telomerase reverse transcriptase and over-expressed in gastric cancer. *Molecular cancer*. 2010;9:132.
13. Ren J, Li W, Liu H, et al. Overexpression of reptin in renal cell carcinoma contributes to tumor malignancies and its inhibition triggers senescence of cancer cells. *Urologic oncology*. 2013;31(7):1358-1366.
14. Rousseau B, Ménard L, Haurie V, et al. Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. *Hepatology (Baltimore, Md)*. 2007;46(4):1108-1118.
15. Sigala B, Edwards M, Puri T, Tsaneva IR. Relocalization of human chromatin remodeling cofactor TIP48 in mitosis. *Experimental cell research*. 2005;310(2):357-369.
16. Izumi N, Yamashita A, Iwamatsu A, et al. AAA+ proteins RUVBL1 and RUVBL2 coordinate PIKK activity and function in nonsense-mediated mRNA decay. *Science signaling*. 2010;3(116):ra27.
17. Grigoletto A, Lestienne P, Rosenbaum J. The multifaceted proteins Reptin and Pontin as major players in cancer. *Biochimica et biophysica acta*. 2011;1815(2):147-157.
18. Huber O, Ménard L, Haurie V, Nicou A, Taras D, Rosenbaum J. Pontin and reptin, two related ATPases with multiple roles in cancer. *Cancer research*. 2008;68(17):6873-6876.
19. Kusch T, Florens L, Macdonald WH, et al. Acetylation by Tip60 is required for selective histone variant exchange at DNA lesions. *Science (New York, NY)*. 2004;306(5704):2084-2087.

20. Etard C, Gradl D, Kunz M, Eilers M, Wedlich D. Pontin and Reptin regulate cell proliferation in early *Xenopus* embryos in collaboration with c-Myc and Miz-1. *Mechanisms of development*. 2005;122(4):545-556.
21. Wood MA, McMahon SB, Cole MD. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. *Molecular cell*. 2000;5(2):321-330.
22. Tarangelo A, Lo N, Teng R, et al. Recruitment of Pontin/Reptin by E2f1 amplifies E2f transcriptional response during cancer progression. *Nature communications*. 2015;6:10028.
23. Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. *Cell*. 2008;132(6):945-957.

## ABSTRACT(IN KOREAN)

## 과발현된 렙틴(Reptin)의 난소암에서 공격적 특성 촉진

지도교수 김재훈

연세대학교 대학원 의학과

김 보 옥

목적: 렙틴(Reptin)은 에이티피아제(ATPase) 상과(superfamily) 일종으로 암화과정에서 다양한 역할을 한다. 하지만 난소암에서 생물학적 임상적 예후가 연구되지 않아 이번연구에서 난소암에서 렙틴의 기능적 역할과 임상적 의의를 연구하였다.

연구방법: 본 연구는 양성 난소 종양 175개, 경계성 난소종양 55개와 난소암 271개의 조직을 포함하였다. 렙틴의 발현을 확인하기 위해 면역조직화학 염색을 시행하고 렙틴의 발현과 임상적 요인들과 관련성을 연구하였다. 렙틴의 기능적 역할을 연구하기 위해 난소암 세포주에서 짧은 간섭 RNA로 렙틴 억제 후 세포주의 침습, 이동, 증식과 세포주기를 조사하고 동물실험으로 종양성장 여부를 측정하였다.

결과: 면역조직화학염색에서 난소암이 정상, 양성 및 경계성 종양에서 보다 렙틴의 발현이 높을 것을 보였다( $p < 0.001$ ). 렙틴이 과발현된 난소암 환자에서 무진행 생존이 감소하였으나 ( $p=0.014$ ) 전체생존은 감소하는 경향을 보였다( $p=0.071$ ).

OVCA429와 TOV112D의 난소암세포주에서 렙틴을 짧은 간섭 RNA로 저발현 시켰을 때 세포증식이 저해되었고( $p < 0.001$ ) 난소암 세포의 이동과 침습이 감소하였다(각각  $p < 0.001$ ). 렙틴을 저발현 시킨 세포주를 마우스에 이식하였을 때 종양의 성장이 비교군의 4.4 cc에 비해 실험군에서 2.1cc와 0.4cc로 의미 있게 성장이 감소하였다(각각  $p \text{ value} < 0.05$ ).

결론: 렙틴은 난소암에서 과발현되었고 과발현 된 난소암 환자에서 무진행 생존이 감소하였다. 렙틴의 억제제는 종양세포의 성장과 생존을 감소시켰다. 이러한 결과로 렙틴은 난소암의 중요한 치료 목표가 될 수 있다.

---

핵심되는 말: 렙틴, 난소암, 무진행 생존, 종양세포생존

## PUBLICATION LIST

1. Kim BW, Cho H, Kim H, et al. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study. *European journal of obstetrics, gynecology, and reproductive biology*. 2012;160(1):100-105.
2. Kim BW, Jeon YE, Cho H, et al. Pre-treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. *The journal of obstetrics and gynaecology research*. 2012;38(1):48-56.